TGFB1 and metabolic disease: Although MYH3 has not been directly linked to metabolic diseases, numerous studies have demonstrated its role in modulating TGF‐β signaling and affecting ATPase activity, which may contribute to conditions such as joint contractures and skeletal muscle abnormalities [60, 61].